Physician profile
Michael Malekan
NPI 1508276239
$4,810.61
in general payments reported to CMS, 2019-2025
15 companies · $810 in 2025
The $810 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,699 · 2020: $859 · 2021: $273 · 2022: $131 · 2023: $401 · 2024: $638 · 2025: $810.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,848.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,848.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,488.43 | 2019-2025 | |
| Pfizer INC. | $590.61 | 2019-2020 | |
| Glaxosmithkline, LLC. | $534.11 | 2021-2023 | Benlysta, Nucala |
| Aurinia Pharma U.S., INC. | $518.16 | 2021-2025 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $349.17 | 2019-2021 | |
| Horizon Therapeutics Plc | $249.83 | 2019-2020 | |
| Celgene Corporation | $249.77 | 2019 | |
| Janssen Biotech, INC. | $198.84 | 2025 | Tremfya, Simponi Aria |
| E.R. Squibb & Sons, L.L.C. | $146.97 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.55 | 2019-2020 | |
| Pacira Therapeutics, INC. | $126.88 | 2019 | |
| Medexus Pharma, INC. | $100.91 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $75.38 | 2024 | Saphnelo |
| Amgen INC. | $31.06 | 2020 | |
| Hikma Pharmaceuticals USA | $12.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Malekan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.